The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers

Kelly A. Metcalfe, Henry T. Lynch, Parviz Ghadirian, Nadine Tung, Ivo A. Olivotto, William D. Foulkes, Ellen Warner, Olufunmilayo Olopade, Andrea Eisen, Barbara Weber, Jane McLennan, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk. Patients were 491 women with stage I or stage II breast cancer, diagnosed from 1975 to 2000 and for whom a BRCA1 or BRCA2 mutation had been identified. Patients were followed from the initial diagnosis of breast cancer until either ovarian cancer, prophylactic oophorectomy, death, or 2002. The medical treatment records and pathology documents were reviewed. Information that was abstracted from the medical charts included date of breast cancer diagnosis, stage of disease, use of chemotherapy, use of radiation therapy, usage of tamoxifen, oophorectomy, recurrence, second malignancy, and vital status. The 10-year actuarial risk of ovarian cancer after breast cancer was 12.7% for BRCA1 carriers and 6.8% for BRCA2 carriers (P = 0.03). The use of tamoxifen (OR = 1.79; P = 0.16) and chemotherapy (OR = 0.59; P = 0.15) did not significantly impact on the risk of subsequent ovarian cancer. Twenty-five percent of the deaths in women with stage I breast cancer were due to a subsequent ovarian cancer. The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease. Breast cancer systemic therapy did not significantly alter the risk of ovarian cancer.

Original languageEnglish
Pages (from-to)222-226
Number of pages5
JournalGynecologic Oncology
Volume96
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Ovarian Neoplasms
Breast Neoplasms
Ovariectomy
Tamoxifen
Mutation
Drug Therapy
Second Primary Neoplasms
Medical Records
Radiotherapy
Therapeutics
Pathology
Recurrence
Incidence

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology

Cite this

Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., ... Narod, S. A. (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic Oncology, 96(1), 222-226. https://doi.org/10.1016/j.ygyno.2004.09.039

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. / Metcalfe, Kelly A.; Lynch, Henry T.; Ghadirian, Parviz; Tung, Nadine; Olivotto, Ivo A.; Foulkes, William D.; Warner, Ellen; Olopade, Olufunmilayo; Eisen, Andrea; Weber, Barbara; McLennan, Jane; Sun, Ping; Narod, Steven A.

In: Gynecologic Oncology, Vol. 96, No. 1, 01.2005, p. 222-226.

Research output: Contribution to journalArticle

Metcalfe, KA, Lynch, HT, Ghadirian, P, Tung, N, Olivotto, IA, Foulkes, WD, Warner, E, Olopade, O, Eisen, A, Weber, B, McLennan, J, Sun, P & Narod, SA 2005, 'The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers', Gynecologic Oncology, vol. 96, no. 1, pp. 222-226. https://doi.org/10.1016/j.ygyno.2004.09.039
Metcalfe, Kelly A. ; Lynch, Henry T. ; Ghadirian, Parviz ; Tung, Nadine ; Olivotto, Ivo A. ; Foulkes, William D. ; Warner, Ellen ; Olopade, Olufunmilayo ; Eisen, Andrea ; Weber, Barbara ; McLennan, Jane ; Sun, Ping ; Narod, Steven A. / The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. In: Gynecologic Oncology. 2005 ; Vol. 96, No. 1. pp. 222-226.
@article{f3dc06e0552143539617d65738ea26b9,
title = "The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers",
abstract = "To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk. Patients were 491 women with stage I or stage II breast cancer, diagnosed from 1975 to 2000 and for whom a BRCA1 or BRCA2 mutation had been identified. Patients were followed from the initial diagnosis of breast cancer until either ovarian cancer, prophylactic oophorectomy, death, or 2002. The medical treatment records and pathology documents were reviewed. Information that was abstracted from the medical charts included date of breast cancer diagnosis, stage of disease, use of chemotherapy, use of radiation therapy, usage of tamoxifen, oophorectomy, recurrence, second malignancy, and vital status. The 10-year actuarial risk of ovarian cancer after breast cancer was 12.7{\%} for BRCA1 carriers and 6.8{\%} for BRCA2 carriers (P = 0.03). The use of tamoxifen (OR = 1.79; P = 0.16) and chemotherapy (OR = 0.59; P = 0.15) did not significantly impact on the risk of subsequent ovarian cancer. Twenty-five percent of the deaths in women with stage I breast cancer were due to a subsequent ovarian cancer. The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease. Breast cancer systemic therapy did not significantly alter the risk of ovarian cancer.",
author = "Metcalfe, {Kelly A.} and Lynch, {Henry T.} and Parviz Ghadirian and Nadine Tung and Olivotto, {Ivo A.} and Foulkes, {William D.} and Ellen Warner and Olufunmilayo Olopade and Andrea Eisen and Barbara Weber and Jane McLennan and Ping Sun and Narod, {Steven A.}",
year = "2005",
month = "1",
doi = "10.1016/j.ygyno.2004.09.039",
language = "English",
volume = "96",
pages = "222--226",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers

AU - Metcalfe, Kelly A.

AU - Lynch, Henry T.

AU - Ghadirian, Parviz

AU - Tung, Nadine

AU - Olivotto, Ivo A.

AU - Foulkes, William D.

AU - Warner, Ellen

AU - Olopade, Olufunmilayo

AU - Eisen, Andrea

AU - Weber, Barbara

AU - McLennan, Jane

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2005/1

Y1 - 2005/1

N2 - To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk. Patients were 491 women with stage I or stage II breast cancer, diagnosed from 1975 to 2000 and for whom a BRCA1 or BRCA2 mutation had been identified. Patients were followed from the initial diagnosis of breast cancer until either ovarian cancer, prophylactic oophorectomy, death, or 2002. The medical treatment records and pathology documents were reviewed. Information that was abstracted from the medical charts included date of breast cancer diagnosis, stage of disease, use of chemotherapy, use of radiation therapy, usage of tamoxifen, oophorectomy, recurrence, second malignancy, and vital status. The 10-year actuarial risk of ovarian cancer after breast cancer was 12.7% for BRCA1 carriers and 6.8% for BRCA2 carriers (P = 0.03). The use of tamoxifen (OR = 1.79; P = 0.16) and chemotherapy (OR = 0.59; P = 0.15) did not significantly impact on the risk of subsequent ovarian cancer. Twenty-five percent of the deaths in women with stage I breast cancer were due to a subsequent ovarian cancer. The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease. Breast cancer systemic therapy did not significantly alter the risk of ovarian cancer.

AB - To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk. Patients were 491 women with stage I or stage II breast cancer, diagnosed from 1975 to 2000 and for whom a BRCA1 or BRCA2 mutation had been identified. Patients were followed from the initial diagnosis of breast cancer until either ovarian cancer, prophylactic oophorectomy, death, or 2002. The medical treatment records and pathology documents were reviewed. Information that was abstracted from the medical charts included date of breast cancer diagnosis, stage of disease, use of chemotherapy, use of radiation therapy, usage of tamoxifen, oophorectomy, recurrence, second malignancy, and vital status. The 10-year actuarial risk of ovarian cancer after breast cancer was 12.7% for BRCA1 carriers and 6.8% for BRCA2 carriers (P = 0.03). The use of tamoxifen (OR = 1.79; P = 0.16) and chemotherapy (OR = 0.59; P = 0.15) did not significantly impact on the risk of subsequent ovarian cancer. Twenty-five percent of the deaths in women with stage I breast cancer were due to a subsequent ovarian cancer. The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease. Breast cancer systemic therapy did not significantly alter the risk of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=10044254427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044254427&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.09.039

DO - 10.1016/j.ygyno.2004.09.039

M3 - Article

VL - 96

SP - 222

EP - 226

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -